VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in ANI Pharmaceuticals, Inc. $ANIP

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 17,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,449,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.08% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the first quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares during the period. Jane Street Group LLC acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $2,706,000. Finally, Norges Bank bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $625,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Down 1.8%

Shares of ANIP stock opened at $70.19 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $99.39. The firm has a market capitalization of $1.61 billion, a PE ratio of 15.13 and a beta of 0.45. The stock has a fifty day moving average of $77.26 and a two-hundred day moving average of $78.19. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same period last year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday. They issued an “outperform” rating and a $104.00 target price on the stock. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $105.57.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen Carey sold 3,313 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the sale, the chief financial officer directly owned 177,543 shares in the company, valued at approximately $15,268,698. The trade was a 1.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the sale, the vice president directly owned 74,424 shares of the company’s stock, valued at approximately $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,425 shares of company stock worth $1,687,370 in the last 90 days. Corporate insiders own 8.10% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.